Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Network analyses identify liver-specific targets for treating liver diseases.

Artikel i vetenskaplig tidskrift
Författare Sunjae Lee
Cheng Zhang
Zhengtao Liu
Martina Klevstig
Bani Mukhopadhyay
Mattias Bergentall
Resat Cinar
Marcus Ståhlman
Natasha Sikanic
Joshua K Park
Sumit Deshmukh
Azadeh M Harzandi
Tim Kuijpers
Morten Grøtli
Simon J Elsässer
Brian D Piening
Michael Snyder
Ulf Smith
Jens Nielsen
Fredrik Bäckhed
George Kunos
Mathias Uhlen
Jan Boren
Adil Mardinoglu
Publicerad i Molecular systems biology
Volym 13
Nummer/häfte 8
ISSN 1744-4292
Publiceringsår 2017
Publicerad vid Institutionen för kemi och molekylärbiologi
Institutionen för medicin, avdelningen för molekylär och klinisk medicin
Språk en
Länkar dx.doi.org/10.15252/msb.20177703
www.ncbi.nlm.nih.gov/entrez/query.f...
Ämneskategorier Klinisk medicin

Sammanfattning

We performed integrative network analyses to identify targets that can be used for effectively treating liver diseases with minimal side effects. We first generated co-expression networks (CNs) for 46 human tissues and liver cancer to explore the functional relationships between genes and examined the overlap between functional and physical interactions. Since increased de novo lipogenesis is a characteristic of nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC), we investigated the liver-specific genes co-expressed with fatty acid synthase (FASN). CN analyses predicted that inhibition of these liver-specific genes decreases FASN expression. Experiments in human cancer cell lines, mouse liver samples, and primary human hepatocytes validated our predictions by demonstrating functional relationships between these liver genes, and showing that their inhibition decreases cell growth and liver fat content. In conclusion, we identified liver-specific genes linked to NAFLD pathogenesis, such as pyruvate kinase liver and red blood cell (PKLR), or to HCC pathogenesis, such as PKLR, patatin-like phospholipase domain containing 3 (PNPLA3), and proprotein convertase subtilisin/kexin type 9 (PCSK9), all of which are potential targets for drug development.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?